Study of QXL138AM for advanced solid tumors and multiple myeloma
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: ovarian, pancreatic, urothelial, renal, hepatocellular, GI, lung, prostate, breast, or multiple myeloma.
- You must have tried standard treatments and they stopped working, or they are not suitable for you.
- You must be 18 years or older.
- You must be able to care for yourself (ECOG score of 0, 1, or 2).
- You must have a measurable tumor or evaluable disease (for myeloma patients, specific criteria apply).
- You must have good organ function and heart health, and agree to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
This trial tests an experimental drug (called QLS5308) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug can shrink tumors or slow their growth, and to find the best dose with manageable side effects.
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
This trial tests a combination of two new drugs (QLS31905 and/or QL1706) with chemotherapy for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.